STOPCAP 1 Programme
Speeding up the evaluation of therapies for metastatic, hormone-sensitive prostate cancer
Speeding up the evaluation of treatments for prostate cancer that has spread beyond the prostate and responds to hormone therapy
What was this study about?
STOPCAP M1 is a worldwide collaborative effort that aims to quickly identify which treatments work best for men with metastatic, hormone-sensitive prostate cancer. This will be done through:
1. Systematic reviews of treatment effects
2. Identification of surrogate outcomes, by trying to find early measurements of prostate cancer control that predict later survival
3. Establishing a repository of patient data, which will be used to tackle new questions about advanced prostate cancer and its treatment as they arise.
For more information, please visit the STOPCAP 1 website.
What difference did this study make?
Please click below for more information about STOPCAP 1 results, so far:
- STOPCAP 1 (M0) – docetaxel, systematic review and aggregate data meta-analysis (Lancet, 2016)
- STOPCAP 1 (M0) – bisphosphonates, systematic review and aggregate data meta-analysis (Lancet 2016)
- STOPCAP 1 (M1) – docetaxel, systematic review and aggregate data meta-analysis
- STOPCAP 1 (M1) – bisphosphonates, systematic review and aggregate data meta-analysis
- STOPCAP 1 (M1) – abiraterone, systematic review and aggregate data meta-analysis, (EJC 2017)
- STOPCAP 1 (M1) - aggregate data network meta-analysis, (Annals Onc 2018)
- STOPCAP 1 (M1) – prostate RT, systematic review and aggregate data meta-analysis, (Eur Urol 2019)
- STOPCAP 1 (M1) – docetaxel, systematic review and individual participant data meta-analysis (Lancet Onc 2023)
Contact details
Who funded the study?
The STOPCAP 1 collaboration is funded by Prostate Cancer UK and the Medical Research Council.
When did it take place?
This programme of research is ongoing.
Where did it take place?
The programme is led by the MRC Clinical Trials Unit at University College London, and brings together the results of trials carried out worldwide.
Who was included?
Trials that randomised men with metastatic hormone-sensitive prostate cancer.
Related News
'25 at 25': Framework for Adaptive Meta-analysis (FAME) for timely, reliable and thorough results
29 Oct 2024
New podcast episode: Who benefits most from a treatment?
12 Mar 2024
New prostate cancer treatments could reach men sooner
22 Feb 2024
Which people with metastatic prostate cancer benefit most from upfront docetaxel?
04 Jul 2023
More News...